Compare ETHZ & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETHZ | CRBP |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.9M | 202.6M |
| IPO Year | N/A | N/A |
| Metric | ETHZ | CRBP |
|---|---|---|
| Price | $10.51 | $10.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $50.29 |
| AVG Volume (30 Days) | ★ 881.1K | 298.4K |
| Earning Date | 01-26-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,110,169.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.58 | $4.64 |
| 52 Week High | $174.60 | $20.56 |
| Indicator | ETHZ | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 44.05 | 36.00 |
| Support Level | $9.33 | $10.05 |
| Resistance Level | $11.82 | $10.82 |
| Average True Range (ATR) | 1.04 | 0.73 |
| MACD | -0.34 | -0.00 |
| Stochastic Oscillator | 22.79 | 8.83 |
ETHZilla Corporation is a technology company in the decentralized finance industry. It seeks to connect financial institutions, businesses and organizations worldwide by enabling secure, accessible blockchain transactions through Ethereum Network protocol implementations. It generates recurring revenues through various DeFi protocols that improve Ethereum network integrity and security. The group enables the seamless tokenization of traditional assets by bringing them on-chain. Leveraging its proprietary protocol solutions, ETHZilla supports DeFi transactions, asset digitization across various Layer 2 Ethereum networks. The platform is focused on delivering tokenization services, DeFi protocol integrations, blockchain analytics, gateways for converting traditional assets to digital forms.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.